Description du projet
Une nouvelle interface d’IA pour aider les survivants du cancer
Les avancées réalisées dans le diagnostic précoce et le traitement du cancer ont considérablement amélioré les chances de survie. Un défi important consiste à garantir que les survivants disposent de la meilleure qualité de vie possible. Le projet ONCORELIEF, financé par l’UE, regroupe les dernières avancées technologiques en sciences de la santé et en psychologie du travail. Il développe un système d’intelligence artificielle (IA) centré sur l’utilisateur afin de créer un assistant numérique, intelligent et intuitif appelé Guardian Angel. Il offrira non seulement une aide personnalisée dans les activités et les tâches post-traitement, mais il proposera également des actions concernant l’état de santé global, l’amélioration du bien-être et les soins de santé actifs des patients. Enfin, Guardian Angel aidera le survivant du cancer à rester impliqué dans un parcours de bien-être qui préservera sa santé durant la période qui suit son traitement.
Objectif
The burden of cancer is rising globally and is estimated to have reached 18.1 million new cases and 9.6 million cancer deaths in 2018. Despite the rising cancer incidence, improvements in early detection and therapeutic treatment have improved cancer survival. As a consequence, the number of cancer survivors is increasing globally, creating the need to improve not only treatment but also wellness and follow‐up care. Cancer treatment often involves combined modalities such as surgery, chemotherapy, and radiotherapy. In the past decades, more effective and targeted therapeutic modalities and less destructive cancer treatments have been developed such as immunotherapy and drug‐targeted therapy. Even so, cancer and its treatment have important physical and psychosocial sequelae. ONCORELIEF is a 36-month action that will leverage the above 6 drivers in order to skillfully and methodologically overcome technical challenges, by introducing new approaches that will allow the utilization of big datasets in order to develop a user-centered AI System to facilitate the integration of QoL assessment instruments through the use of PROMs and PREMs in order to improve post-treatment health status, increase the wellbeing, and follow‐up care of cancer patients. This will be achieved through an intuitive smart digital assistant (Guardian Angel), able to provide personalized support in post-treatment activities and tasks, suggest actions regarding the patients' overall health-status, improved wellbeing and active health-care and ultimately maintain him/her engaged on a wellness journey that will safeguard his/her health over the foreseeable prolonged post-cancer treatment period. To achieve this, ONCORELIEF builds on the combined knowhow of its interdisciplinary industry-driven consortium that brings together state-of-the-art technological skills, design thinking methodology and occupational psychology/health sciences.
Champ scientifique
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
E14 3BS London
Royaume-Uni
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.